Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Depreciation & Amortization (CF): 2018-2024

Historic Depreciation & Amortization (CF) for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Dec 2024 value amounting to $3.5 million.

  • Arcturus Therapeutics Holdings' Depreciation & Amortization (CF) fell 11.11% to $800,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 9.60%. This contributed to the annual value of $3.5 million for FY2024, which is 18.13% up from last year.
  • Arcturus Therapeutics Holdings' Depreciation & Amortization (CF) amounted to $3.5 million in FY2024, which was up 18.13% from $3.0 million recorded in FY2023.
  • Arcturus Therapeutics Holdings' Depreciation & Amortization (CF)'s 5-year high stood at $3.5 million during FY2024, with a 5-year trough of $900,000 in FY2020.
  • Over the past 3 years, Arcturus Therapeutics Holdings' median Depreciation & Amortization (CF) value was $3.0 million (recorded in 2023), while the average stood at $2.7 million.
  • Data for Arcturus Therapeutics Holdings' Depreciation & Amortization (CF) shows a peak YoY spiked of 96.46% (in 2023) over the last 5 years.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Depreciation & Amortization (CF) (Yearly) stood at $900,000 in 2020, then skyrocketed by 33.33% to $1.2 million in 2021, then climbed by 27.25% to $1.5 million in 2022, then spiked by 96.46% to $3.0 million in 2023, then rose by 18.13% to $3.5 million in 2024.